NCT00267592View on ClinicalTrials.gov

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

February 28, 2011

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Talampanel

Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.

RADIATION

Radiation Therapy (RT) 5 days a week +

DRUG

temozolomide(TMZ) 75mg

temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks

DRUG

adjuvant TMZ 200mg

adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00267592 - Safety and Efficacy of Talampanel in Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter